890,754 Shares in Septerna, Inc. $SEPN Acquired by Janus Henderson Group PLC

Janus Henderson Group PLC purchased a new position in shares of Septerna, Inc. (NASDAQ:SEPN) during the first quarter, HoldingsChannel reports. The firm purchased 890,754 shares of the company’s stock, valued at approximately $21,334,000.

Several other institutional investors have also added to or reduced their stakes in the stock. Goldman Sachs Group Inc. boosted its stake in shares of Septerna by 86.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock valued at $75,698,000 after purchasing an additional 1,260,409 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Septerna by 7.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,518,757 shares of the company’s stock worth $28,568,000 after purchasing an additional 104,394 shares in the last quarter. ADAR1 Capital Management LLC grew its stake in Septerna by 38.9% in the third quarter. ADAR1 Capital Management LLC now owns 1,176,491 shares of the company’s stock valued at $22,130,000 after acquiring an additional 329,264 shares during the period. First Light Asset Management LLC grew its position in Septerna by 18.0% in the 1st quarter. First Light Asset Management LLC now owns 732,860 shares of the company’s stock valued at $17,611,000 after purchasing an additional 112,049 shares during the period. Finally, VR Adviser LLC grew its holdings in shares of Septerna by 13.0% during the third quarter. VR Adviser LLC now owns 610,808 shares of the company’s stock valued at $11,489,000 after buying an additional 70,355 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Stifel Nicolaus began coverage on Septerna in a report on Friday, May 1st. They set a “buy” rating and a $43.00 price target for the company. Guggenheim dropped their price objective on Septerna from $52.00 to $45.00 and set a “buy” rating on the stock in a research note on Wednesday, July 1st. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Septerna in a report on Wednesday, July 1st. Truist Financial lifted their target price on Septerna from $35.00 to $43.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.89.

Septerna Stock Up 1.5%

Shares of Septerna stock opened at $34.98 on Tuesday. Septerna, Inc. has a 12-month low of $10.62 and a 12-month high of $38.04. The firm has a market cap of $1.58 billion, a PE ratio of -43.18 and a beta of 2.29. The company’s fifty day simple moving average is $33.72 and its two-hundred day simple moving average is $28.67.

Septerna (NASDAQ:SEPN) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.23. The business had revenue of $26.52 million during the quarter, compared to analyst estimates of $16.98 million. Septerna had a negative return on equity of 12.72% and a negative net margin of 49.88%. As a group, sell-side analysts expect that Septerna, Inc. will post -1.59 earnings per share for the current fiscal year.

Insider Transactions at Septerna

In other Septerna news, SVP Daniel D. Long sold 15,000 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $35.51, for a total value of $532,650.00. Following the completion of the sale, the senior vice president directly owned 96,412 shares in the company, valued at $3,423,590.12. This trade represents a 13.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Samira Shaikhly sold 11,798 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $30.06, for a total value of $354,647.88. Following the completion of the transaction, the insider owned 793 shares of the company’s stock, valued at approximately $23,837.58. The trade was a 93.70% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 44,494 shares of company stock valued at $1,469,391. 5.80% of the stock is owned by insiders.

Septerna Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.